Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis

Camille C Gunderson1, Rangasudhagar Radhakrishnan2, Rohini Gomathinayagam3, Sanam Husain4, Sheeja Aravindan2, Kathleen M Moore1, Danny N Dhanasekaran2,3 and Muralidharan Jayaraman2,3

1Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 2Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 4Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

ABSTRACT: Clinical management of gynecological cancer begins by optimal debulking with first-line platinum-based chemotherapy. However, in ~80% patients, ovarian cancer will recur and is lethal. Prognostic gene signature panel identifying platinum-resistance enables better patient stratification for precision therapy. Retrospectively collected serum from 11 “poor” (<6 months progression free interval [PFI]) and 22 “favorable” (>24 months PFI) prognosis patients, were evaluated using circulating cell-free DNA (cfDNA). DNA from both groups showed 50 to 10,000 bp fragments. Pairwise analysis of sequenced cfDNA from patients showed that gene dosages were higher for 29 genes and lower for 64 genes in poor than favorable prognosis patients. Gene ontology analysis of higher dose genes predominantly grouped into cytoskeletal proteins, while lower dose genes, as hydrolases and receptors. Higher dosage genes searched for cancer-relatedness in Reactome database indicated 15 genes were referenced with cancer. Among them 3 genes, TGFBR2, ZMIZ2, and NRG2, were interacting with more than 4 cancer-associated proteins. Protein expression analysis of tumor samples indicated that TGFBR2 was downregulated and ZMIZ2 was upregulated in poor prognosis patients. Our results indicate that the cfDNA gene dosage combined with protein expression in tumor samples can serve as gene signature panel for prognosis determination amongst ovarian cancer patients.

KEYWORDS: Biomarker, cfDNA, TGFBR2, ZMIZ2, ovarian cancer

Introduction

Cancer heterogeneity exists both functionally and morphologically, amplifying the challenges of effectively treating the disease.1 Therapy stratification tailored to suit the precise characteristics of each patient yields a better prognosis.2 Biopsies with specific indicative property, also known as biomarkers, can be expression levels of proteins or RNA, copy number variation of specific genes, micro-RNA, or non-coding RNA.3 Genomic, proteomic, and other “omic” approaches to evaluate tumor samples have aided in developing gene panels of predictive biomarkers, which identify patients who will respond to distinct therapy strategies.4 In order to minimize invasiveness in generating samples, liquid biopsies from body fluids such as blood, saliva, and urine have been investigated to develop biomarker gene panels.5

For nearly 70 years, we have known that there are circulating nucleic acids within the blood,6 but the concept gained importance in the late 1970s when serum of cancer patients was noted to have a higher concentration of nucleic acids compared to healthy individuals.7 Hypothesizing that circulating tumor cell-free DNA (cfDNA) can provide potential clues related to primary and metastatic tumors, studies on these DNA have been pursued in many cancer types.8 Ovarian cancer is the most lethal of all gynecologic malignancies. For 2021, it is estimated that there would be 21,410 new cases and 13,770 deaths.9 Despite response to first-line therapy, ~80% of patients will experience disease recurrence, and unfortunately, emergence of resistance to chemotherapy is inevitable for most patients.10-12 Platinum-based chemotherapy is the single most active treatment strategy for ovarian cancer, and the underlying mechanisms of resistance to platinum-based chemotherapy are most likely multifactorial.13-15 These include neutralizing alterations by cancer cells to platinum-based intercalated DNA adducts and epigenetic responses of the chemotherapy.16 Hence, resistance to platinum-based chemotherapy is a major challenge for clinicians, with median progression free survival of 4 months, and median overall survival of 12 months for these patients.17,18 Development of a gene signature panel for reliable prediction of prognosis prior to manifestation of chemo-resistance may help risk-stratify patients with more aggressive disease for whom treatment approaches could be altered.
Although cancer patients have higher concentration of cfDNA than healthy individuals, the concentration and gene composition of cfDNA vary amongst cancer patients. Prior research has shown that DNA encoding oncogenes, tumor suppressor genes, microsatellite alterations, and hypermethylated genes are circulating in the plasma of cancer patients. cfDNA levels in the serum has been shown to predict response to therapy, and qualitative evaluation of cfDNA methylation has been used to differentiate cancer survival. However, the development of precise gene signature panels with specific genes in the serum is incomplete. Rapid and accurate methods of determination may provide better prediction of response to anti-cancer therapies. Based on this rationale, we sought to develop a precise prognostic gene signature panel of cfDNA genes in poor prognosis (platinum free interval [PFI] < 6 months) versus favorable prognosis (PFI > 24 months) patients with high grade serous ovarian cancer.

Our results on sequencing the cfDNA isolated from poor and favorable prognosis patient serum samples indicated that a distinct cluster of genes as DNA fragments are circulating in the blood. Based on the quantification of these genes, they were grouped as genes of higher or lower dosage in the poor prognosis patients compared to favorable prognosis patients. Those high dose genes observed in poor prognosis patient samples were compared to the Reactome database for cancer relevance. Transforming growth factor, beta receptor II (TGFBR2) and Zinc finger, MIZ-type containing 2 (ZMIZ2), which indicated multiple interactions with cancer associated proteins, were verified for protein expression in patient tumor tissues. Based on our study, we propose a novel multi-factorial approach to develop a gene signature panel, with genes identified in cfDNA fragments of patient serum and their protein expression levels in tumor tissues that could demarcate prognosis in ovarian cancer patients.

Materials and Methods

Patient selection

Eligibility was restricted to women with stage IIIC high grade serous carcinoma of the ovary, fallopian tube, or peritoneum who underwent primary debulking surgery followed by adjuvant platinum-based chemotherapy. All women were treated by gynecologic oncologists at Stephenson Cancer Center at The University of Oklahoma Health Sciences Center. In order to compare groups with distinct prognosis and clinical course, patients were dichotomized into 2 groups based on their time from completion of platinum-based chemotherapy until first recurrence (PFI). PFI < 6 months was selected as the poor prognostic group, and PFI ≥ 24 months defined the favorable prognostic cohort. The study methods and experimental protocols were approved by the University of Oklahoma Health Science Center, Office of Human Research Participant Protection, Institutional Review Board (IRB approval # 6404). The authors confirm that the methods were carried out in accordance with relevant guidelines and regulations. All patients in the study were above 18 years and were informed of the nature of the study and provided written consent, prior to treatment and collection of samples. The storage of samples was done by Stephenson Cancer Center Biospecimen core. Deidentified serum and tissue samples were made available to the researchers for this study. TMA of 126 ovarian cancer patients and pertaining deidentified patient characteristics were graciously provided by the authors of earlier publication.

cfDNA isolation

cfDNA from the 2 ml of retrospectively collected serum from each patient was isolated using Quick-cfDNA™ Serum & Plasma Kit (Zymo Research) following the manufacturer’s protocol. The DNA was eluted in 25 μl of elution buffer and the quantification was done using Qubit kit on a Qubit fluorometer (Thermo Fisher). An estimated 1 ng/μl of sample were loaded on High Sensitivity DNA chip (Agilent) and run on a Bioanalyzer 2100 (Agilent). The DNA integrity and purity were evaluated. The electrophrograms were generated using the 2100 expert software (Agilent).

Sequencing and analysis of cfDNA

For sequencing of the cfDNA, a total of 1 ng of cfDNA was used to construct library using the Nextera XT DNA library preparation kit (Illumina). The samples were sequenced on MiSeq system (Illumina) at 2 × 250 base pair read length. The sequencing yielded about 60 million reads and the quality averages were ≥Q30 in 71% or more reads. The sequences were aligned against the human genome sequence (GRCh build 38) assembled by Genome Reference Consortium and a pairwise sequence data analysis was performed using GeneSifter analysis software (Perkin Elmer). Annotated genes were normalized to their reads per kilobase per million mapped reads (RPKM) for each sample and gene count were averaged for each group of patients. Gene copy number variations were statistically evaluated following the Welch’s t-test method with P < .05. Volcano plot for the genes that showed fold change of >1and < −1 in poor compared to favorable prognosis patient groups was performed. Heatmap for the gene copy number variation and the ratio of poor prognosis patient genes, grouped either higher (≥1.5-fold) or lower (≤ −1.5-fold) compared to favorable prognosis patient genes, were generated using ggplot2 algorithm of the R program.

Gene ontology analysis

Both groups, high and low dose genes, were analyzed using the PANTHER (protein annotation through evolutionary relationship) system for their gene ontology. Classification of these genes into various groups was based on their biological processes, protein class, or molecular functions. This was
Immunohistochemical staining of tissue microarray (TMA)

All the concomitant patient FFPE samples were collected. Hematoxylin-Eosin (HE) stained sections were marked for tumor by a pathologist. Triplicate tumor cores of 1 mm diameter were set in an empty block using Tissue Arrayer ATA110C (Veridiam) to develop a TMA. For control, normal uterus and fallopian tube were used. The TMA was constructed at the Stephenson Cancer Center’s Tissue Pathology Shared Resource using standard methodology. TMA of 126 ovarian cancer patient tumor samples were provided by the authors of an earlier publication. IHC-staining of both TMA with the antibodies of interest was carried out at the SCC Tissue Pathology Shared Resource that utilizes automated Leica Bond III for IHC staining. Antibodies used were TGFBR2 (1:400; BIOSS) and ZMIZ2 (1:30; Novus Biologicals). IHC staining method were followed as described in publication, briefly, FFPE tissues were sectioned. Deparaffinization and rehydration were performed on an automated Multistainer (Leica ST5020). Subsequently, these slides were transferred to the Leica Bond III™, where target retrieval and peroxidase-blocking were performed. It was followed by the primary antibody incubation for 60 minutes and Poly-HRP IgG reagent was used as secondary antibody. DAB (3,3’-diaminobenzidine tetrahydrochloride) was used as chromogen and slides were counterstained with hematoxylin. Stained slides were dehydrated (Leica ST5020) and mounted (Leica MM24). Antibody specific positive control and negative control (omission of primary antibody) were parallel-stained.

Scanning and analysis of IHC slides

Methods for scanning and analysis of the IHC stained slides have been adapted similar to the earlier publication. Briefly, the IHC stained TMA slides were scanned using an Aperio slide scanner (Leica Inc.). The TMA were segmented, and individual spots were assigned to respective patients using the TMA lab software, which works in conjunction with the spectrum software from Leica Aperio. Quantification of the various protein staining was done using Spectrum software (Leica Inc.).

Software used

Cytoscape 3.4v with plugin for Reactome FIViz app 6 with FI network style for connections. R program with ggplot2 package using R-Studio was used to generate the heatmap for the genes. Multiple unpaired t-tests were done for patient analysis and for individual protein expression studies t-tests were done for all the TMA analysis. All statistical analysis was done using Graphpad Prism 7.0v.

Results

Two cohorts of retrospective ovarian cancer patient samples were used in this study. The primary cohort for the cfDNA analysis included 33 patients with either <6-month (poor prognosis; 11 patients) or ≥24-month (favorable prognosis; 22 patients) PFI. In order to maintain clinico-pathological uniformity, only patients with stage IIIC high grade serous ovarian cancer who underwent primary debulking surgery were included in the study. The majority of patients were Caucasian with similar BMI and initial serum CA125 concentration (units/milliliter). On average, women diagnosed at younger age (61.2 ± 1.7 year) favored longer (≥24 months) survival (Table 1). A secondary cohort included 126 ovarian cancer patients and the tumor samples from these patients represented in a TMA were analyzed for validation of the results. Adapting the above criteria, this cohort was divided into 3 categories, poor prognosis (26 patients), favorable prognosis (32 patients), and rest of the patients between 6 and 24 months PFI (68 patients). The characteristics of the poor and favorable prognosis patients had similar BMI, initial CA125 concentration, and age of diagnosis (Supplemental Table 1).

Table 1. Clinical characteristics of patients selected in the study.

| CHARACTERISTICS       | FAVORABLE PROGNOSIS | POOR PROGNOSIS | P-VALUE |
|-----------------------|---------------------|----------------|---------|
| Age at diagnosis      | 58.4 ± 2.3          | 67 ± 3.8       | .0355   |
| Platinum free interval| 47.4 ± 5.8          | 2 ± 0.7        | .0001   |
| Body mass index       | 24.14 ± 1.4         | 26.07 ± 2.0    | .2222   |
| Initial CA125 (units/ml) | 1568.1 ± 469.6    | 1824.2 ± 799.3 | .3931   |
| cfDNA conc (ng/μl)   | 1.53 ± 0.5          | 1.51 ± 0.6     | .8692   |
used to extract the cfDNA. Concentration of cfDNA in the serum did not vary among both groups of patients (Table 1). The molecular size of cfDNA fragments obtained in the serum were between 50 and 10,000 base pairs (Figure 1A and B).

An unbiased next generation sequencing to delineate the gene composition in the cfDNA of the test samples was carried out following previously published procedures.\textsuperscript{31,32} The cfDNA fragments were sequenced and annotated against the human genome sequences (GRCh build 38). Copy number variation of the cfDNA for each gene for each group of patients was calculated. Comparing the gene copy number variations between the poor and favorable prognosis patients, gene dosage for each group of patients was calculated. A volcano plot was generated following previously published methods.\textsuperscript{33} Using a cutoff of 1.5-fold gene dosage and \(<0.01\ P\)-value threshold, 29 genes were identified to be of higher and 64 genes of lower gene dosages in the poor prognosis compared to favorable prognosis patients (Tables 2 and 3).

**Figure 1.** Identification of higher and lower dose of genes in the cfDNA isolated from serum of platinum resistant (poor prognosis) and sensitive (favorable prognosis) patients. (A and B) Chromatogram generated for cfDNA isolated from serum of patients using High sensitivity DNA analysis chip. (A) Favorable and (B) Poor prognosis. (C) Volcanic plot showing genes of higher and lower dose in sequenced cfDNA isolated from patients with poor and favorable prognosis. \(P\)-value cutoff: 0.05 (red line); lower threshold: 1.5 (green line); higher (red spheres); and lower (green spheres) genes.

Genes and signaling pathway proteins that may play a crucial role, an arbitrary gene dosage cut-off of 1.5-fold variation was chosen based on previous studies.\textsuperscript{34,35} Gene ontology analysis on genes

Gene ontology enrichment analysis was performed using the PANTHER classification system.\textsuperscript{28} A heatmap for the copy number variation and ratio of the higher dose genes in the poor and favorable prognosis patients were plotted (Figure 2A; Table 2). Similarly, a heatmap of the copy number variation was plotted for the 69 lower dosage genes that had 1.5-fold or lower fold ratio in the poor prognosis compared to favorable prognosis patients (Figure 3A; Table 3).
Table 2. cfDNA higher dosage genes in the poor prognosis ovarian cancer patients.

| GENE     | GENE NAME                                                                 | FAVORABLE | POOR  | P-VALUE |
|----------|---------------------------------------------------------------------------|-----------|-------|---------|
| MVP      | Major vault protein                                                       | 4.14      | 7.89  | .0002   |
| C16orf53 | Chromosome 16 open reading frame 53                                       | 2.51      | 4.61  | .0014   |
| PLEC1    | Plectin 1, intermediate filament binding protein 500kDa                  | 7.79      | 13.50 | .0020   |
| DLGAP2   | Disks, large (Drosophila) homolog-associated protein 2                    | 4.36      | 7.41  | .0022   |
| KRT9     | Keratin 9                                                                 | 1.41      | 2.67  | .0024   |
| KDM5C    | Lysine (K)-specific demethylase 5C                                        | 4.42      | 8.08  | .0025   |
| MGAT4B   | Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B | 1.61      | 3.84  | .0029   |
| ZMIZ2    | Zinc finger, MIZ-type containing 2                                        | 3.43      | 5.65  | .0035   |
| C17orf68 | Chromosome 17 open reading frame 68                                       | 3.83      | 7.25  | .0036   |
| GPR176   | G protein-coupled receptor 176                                            | 2.48      | 4.15  | .0036   |
| KIF17    | Kinesin family member 17                                                 | 2.71      | 5.06  | .0043   |
| ADAMTSL3 | ADAMTS-like 3                                                             | 3.96      | 6.58  | .0045   |
| UNC5B    | Unc-5 homolog B (C. elegans)                                              | 2.82      | 4.83  | .0052   |
| CORO6    | Coronin 6                                                                 | 1.63      | 3.67  | .0062   |
| PANX2    | Pannexin 2                                                                | 1.63      | 2.83  | .0063   |
| DKFZp686O24166 | Hypothetical protein DKFZp686O24166                                   | 2.88      | 4.77  | .0068   |
| HIP1R    | Huntingtin interacting protein 1 related                                  | 2.86      | 4.99  | .0069   |
| QRIC2    | Glutamine rich 2                                                          | 3.78      | 7.37  | .0072   |
| NRG2     | Neuregulin 2                                                              | 1.84      | 3.29  | .0073   |
| COL4A3   | Collagen, type IV, alpha 3 (Goodpasture antigen)                          | 2.54      | 4.38  | .0074   |
| CA12     | Carbonic anhydrase XII                                                    | 2.15      | 3.78  | .0076   |
| MYO1H    | Myosin IH                                                                 | 2.49      | 4.27  | .0088   |
| ELF3     | E74-like factor 3 (ets domain transcription factor, epithelial-specific) | 1.97      | 3.77  | .0090   |
| TGFBR2   | Transforming growth factor, beta receptor II (70/80kDa)                   | 1.98      | 3.90  | .0091   |
| LOC653781 | Similar to protein expressed in prostate, ovary, testis, and placenta 2  | 1.59      | 3.15  | .0093   |
| PKP1     | Plakophilin 1 (ectodermal dysplasia/skin fragility syndrome)              | 3.95      | 6.47  | .0094   |
| DGCR14   | DiGeorge syndrome critical region gene 14                                 | 2.16      | 4.70  | .0094   |
| C1orf2   | Chromosome 1 open reading frame 2                                          | 1.79      | 3.47  | .0094   |
| SLC10A3  | Solute carrier family 10 (sodium/bile acid cotransporter family), member 3 | 1.44      | 2.91  | .0096   |

Table 3. cfDNA lower dosage genes in the poor prognosis ovarian cancer patients.

| GENE     | GENE NAME                                                                 | FAVORABLE | POOR  | P-VALUE |
|----------|---------------------------------------------------------------------------|-----------|-------|---------|
| OSBP     | Oxysterol binding protein                                                 | 2.88      | 1.32  | .0001   |
| ARFGAP2  | ADP-ribosylation factor GTPase activating protein 2                       | 3.00      | 1.63  | .0002   |
| FAM105A  | Family with sequence similarity 105, member A                             | 3.39      | 1.11  | .0003   |
| ZNF652   | Zinc finger protein 652                                                   | 3.52      | 1.81  | .0007   |

(Continued)
### Table 3. (Continued)

| GENE                | GENE NAME                                           | FAVORABLE | POOR | P-VALUE |
|---------------------|-----------------------------------------------------|-----------|------|---------|
| CTNNA2              | Catenin (cadherin-associated protein), alpha 2      | 2.44      | 1.09 | .0008   |
| C6                  | Complement component 6                             | 2.49      | 1.16 | .0008   |
| RAGE                | Renal tumor antigen                                | 2.08      | 1.02 | .0009   |
| TBC1D8B             | TBC1 domain family, member 8B (with GRAM domain)    | 2.19      | 1.12 | .0011   |
| CCDC120             | Coiled-coil domain containing 120                  | 3.14      | 1.53 | .0011   |
| UBE2L3              | Ubiquitin-conjugating enzyme E2L 3                  | 2.57      | 1.21 | .0012   |
| LOC100130698        | Hypothetical LOC100130698                          | 4.71      | 2.24 | .0016   |
| PBX1                | Pre-B-cell leukemia homeobox 1                      | 2.99      | 1.56 | .0021   |
| GLUD2               | Glutamate dehydrogenase 2                          | 2.60      | 1.17 | .0022   |
| STIM1               | Stromal interaction molecule 1                      | 3.33      | 1.70 | .0024   |
| DGKK                | Diacylglycerol kinase, kappa                        | 4.50      | 2.28 | .0025   |
| DNAL1               | Dynein, axonemal, light chain 1                     | 2.79      | 1.40 | .0027   |
| POU2F3              | POU class 2 homeobox 3                              | 2.52      | 1.17 | .0031   |
| ALG13               | Asparagine-linked glycosylation 13 homolog (S. cerevisiae) | 2.99 | 1.53 | .0032 |
| FOSL2               | FOS-like antigen 2                                  | 3.78      | 2.14 | .0036   |
| FKBP9L              | FKS06 binding protein 9-like                       | 2.15      | 1.21 | .0038   |
| TM4SF18             | Transmembrane 4I six family member 18              | 2.53      | 1.35 | .0038   |
| POLQ                | Polymerase (DNA directed), theta                    | 2.93      | 1.48 | .0044   |
| CD163L1             | CD163 molecule-like 1                               | 3.37      | 1.82 | .0045   |
| FAM55C              | Family with sequence similarity 55, member C       | 3.94      | 2.04 | .0045   |
| FAM123B             | Family with sequence similarity 123B               | 7.65      | 4.27 | .0047   |
| GPR119              | G protein-coupled receptor 119                     | 2.61      | 1.33 | .0047   |
| IDE                 | Insulin-degrading enzyme                            | 2.76      | 1.41 | .0048   |
| SLC22A17            | Solute carrier family 22, member 17                 | 2.34      | 1.13 | .0048   |
| CNTLN               | Centlein, centrosomal protein                      | 3.63      | 1.75 | .0050   |
| ZNF235              | Zinc finger protein 235                            | 2.90      | 1.67 | .0054   |
| GPR112              | G protein-coupled receptor 112                     | 7.12      | 4.15 | .0056   |
| EAF1                | ELL associated factor 1                             | 3.01      | 1.62 | .0056   |
| TRIM13              | Tripartite motif-containing 13                      | 2.51      | 1.36 | .0061   |
| NPY2R               | Neuropeptide Y receptor Y2                         | 2.60      | 1.40 | .0061   |
| RRP8                | Ribosomal RNA processing 8, methyltransferase, homolog (yeast) | 2.73 | 1.42 | .0061 |
| PCYT1B              | Phosphate cytidylyltransferase 1, choline, beta    | 4.02      | 2.16 | .0062   |
| CRYBG3              | Beta-gamma crystallin domain containing 3           | 5.00      | 2.85 | .0062   |
| CD207               | CD207 molecule, langerin                           | 2.39      | 1.34 | .0065   |
| XRN1                | 5-3 exoribonuclease 1                              | 2.40      | 1.51 | .0068   |
| ZNF208              | Zinc finger protein 208                            | 4.46      | 2.40 | .0069   |

(Continued)
Table 3. (Continued)

| GENE   | GENE NAME                                                                 | FAVORABLE | POOR  | P-VALUE |
|--------|---------------------------------------------------------------------------|-----------|-------|---------|
| KIAA1919 | KIAA1919                                                                 | 2.48      | 1.18  | .0070   |
| SLC22A4 | Solute carrier family 22 (organic cation/ergothioneine transporter), member 4 | 2.12      | 1.15  | .0070   |
| MCART6  | Mitochondrial carrier triple repeat 6                                      | 3.09      | 1.39  | .0070   |
| SSR1    | Signal sequence receptor, alpha                                            | 3.30      | 1.94  | .0070   |
| PREX2   | Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 2     | 2.54      | 1.31  | .0072   |
| MYH16   | Myosin, heavy chain 16 pseudogene                                         | 2.82      | 1.44  | .0074   |
| LRRC33  | Leucine rich repeat containing 33                                         | 2.76      | 1.31  | .0074   |
| CD96    | CD96 molecule                                                              | 2.43      | 1.28  | .0076   |
| PCDH15  | Protocadherin 15                                                           | 4.24      | 2.12  | .0079   |
| ALG11   | Asparagine-linked glycosylation 11, alpha-1,2-mannosyltransferase homolog (yeast) | 2.50      | 1.42  | .0083   |
| TREX1   | Three prime repair exonuclease 1                                          | 2.50      | 1.46  | .0083   |
| DOK6    | Docking protein 6                                                          | 3.81      | 2.28  | .0089   |
| ITPR1   | Inositol 1 and 4,5-triphosphate receptor, type 1                           | 6.77      | 4.43  | .0091   |
| ZDHHC22 | Zinc finger, DHHC-type containing 22                                       | 3.18      | 1.69  | .0091   |
| TFAP2E  | Transcription factor AP-2 epsilon (activating enhancer binding protein 2 epsilon) | 2.73      | 1.56  | .0093   |
| NCBP1   | Nuclear cap binding protein subunit 1and 80kDa                            | 2.58      | 1.35  | .0093   |
| CASC5   | Cancer susceptibility candidate 5                                          | 2.35      | 1.42  | .0094   |
| MPL     | Myeloproliferative leukemia virus oncogene                                 | 2.79      | 1.74  | .0094   |
| LRRC66  | Leucine rich repeat containing 66                                          | 2.55      | 1.65  | .0095   |
| LSM8    | LSM8 homolog, U6 small nuclear RNA associated (S. cerevisiae)              | 3.59      | 1.99  | .0095   |
| NONO    | Non-POU domain containing, octamer-binding                                | 2.11      | 1.11  | .0096   |
| NDRG3   | NDRG family member 3                                                      | 2.50      | 1.29  | .0096   |
| ANKRD54 | Ankyrin repeat domain 54                                                  | 2.90      | 1.35  | .0096   |
| KCNJ16  | Potassium inwardly-rectifying channel, subfamily J, member 16             | 2.32      | 1.43  | .0100   |

**Higher dose genes.** The 29 genes identified as higher dose genes in poor outcome patients were subjected to gene ontology grouping. Based on the biological processes genes showed clustering toward cellular processes (29%), developmental processes (14%), and cellular biogenesis (12%) (Figure 2B). Many of these genes were classified as cytoskeletal proteins (23%), and about 9% each as enzyme modulators, transcription factors, nucleic acid binding proteins, receptors, and signaling proteins (Figure 2C). Furthermore, these factors reflect in their molecular function classification, attributing them to protein binding function (47%) and catalytic activity (27%) (Figure 2D).

**Lower dose genes.** Gene ontology analysis showed that these lower dose 64 genes were involved in cellular processes (36%), metabolic processes (18%), stimulus response (13%), and biological regulations (11%) of the cell (Figure 3B). Distinctly different from higher dosage genes, protein classification showed a higher number of them as hydrolases (16%), receptors (16%), and nucleic acid binding proteins (14%) (Figure 3C). Agreeing with the biological process grouping, the molecular function classification of these genes indicated a greater number of lower dosage genes grouped with protein binding (40%), catalytic (21%), or receptor activity (16%) (Figure 3D).

**Interaction nodes analysis of the higher dosage genes**

Reactome database was searched using Cytoscape functional interaction network analysis module for cancer linked genes, to determine which of the higher dose genes formed nodes of interaction with cancer associated genes.36 Figure 4 shows the degree-based circular layout representation of the analysis.
Polyubiquitin-C precursor (UBC) is one of the linker genes used in the network analysis that showed 17 nodes, which had the highest number of nodes amongst all proteins (Supplemental Table 2). However, among the cfDNA higher dose genes, Transforming growth factor, beta receptor II (TGFBR2) was the hub for highest number of 5 nodes (Supplemental Table 2). Other major proteins that formed at least 2 node hubs were Zinc finger, MIZ-type containing 2 (ZMIZ2), Neuregulin 2 (NRG2), E74-like factor 3 (ets domain transcription factor) (ELF3), Unc-5 homolog B (UNC5B), and Huntingtin interacting protein 1 related (HIP1R) (Supplemental Table 2).

Validation of interaction network hub proteins of cfDNA in patient tumor samples

The higher dose genes, TGFBR2 and ZIMZ2, identified may be a consequence of gene amplification, which can lead to upregulation of the protein in the cancer cells. Hence, immunohistochemistry (IHC) staining of TGFBR2 (Figure 5A, i) and ZIMZ2 (Figure 5B, i) were carried out on FFPE sections of the TMA constructed from ovarian cancer patient tumor samples. Since normal ovarian tissue was not available at that time of analysis, normal uterus and fallopian tube tissues were used as controls. The cell membrane receptor, TGFBR2 membranous expression IHC analysis showed increased expression in favorable patients compared to poor prognosis patients (Figure 5A, ii). IHC analysis of ovarian cancer patients for ZMIZ2 showed increased nuclear expression in poor patients compared to the favorable prognosis group of ovarian cancer patients (Figure 5B, ii). The expression levels of TGFBR2 and ZIMZ2 in the second cohort of 126 ovarian cancer patient tumor TMA was analyzed by IHC staining for the proteins. IHC analysis of TGFBR2 membranous expression level decreased in poor prognosis (Supplemental Figure 1A), while ZIMZ2 expression level increased in poor prognosis patients (Supplemental Figure 1B).
Discussion

Resistance to platinum-based therapy is a major clinical challenge in caring for women with ovarian cancer. Clinicians lack tools to preemptively identify platinum resistance, which cripples their effort to risk-stratify treatment options for ovarian cancer patients. An ideal tool would be minimally invasive and rapidly testable method with high fidelity. Toward this goal, circulating tumor cell-free DNA (cfDNA) in the retrospective serum of poor and favorable prognosis patients, which were collected at the time of diagnosis, was analyzed herein. Hence, identification of prognostic gene signature that differentiate poor (PFI < 6 months) versus favorable (PFI > 24 months) prognosis patients, dichotomized based on the time to their first recurrence, was analyzed in this study.

Previous studies have shown that the cfDNA in the serum has multiple origins including apoptotic or necrotic tumor cells, exosomes, macrophage activity, and release by normal cells. The differential profile of genetic signatures in cfDNA could be the result of apoptotic cancer cell derived DNA, chromosomal gene amplification/deletion, circulating tumor cell derived DNA, or DNA specifically released as intratumoral signaling conduits by the cancer cells. Nevertheless, it can be posited that the cfDNA profile from poor versus favorable prognosis patients will exhibit variation in their respective gene composition. Hence, understanding the gene composition based on the cfDNA sequences would shed more light on the behavior of those cells that release the DNA.

Our sequence analyses of the cfDNA indicated that the samples from poor-prognosis patients exhibited 29 genes at higher dosage and 64 genes at lower dosage levels (Figure 1C; Tables 2 and 3). Many of the genes in the higher dosage group clustered toward functions essential in cancer cell invasion and...
metastasis whereas the gene signature from the lower group consists mostly of genes encoding receptors and enzymes involved in growth inhibition or tumor suppression. Reasoning that the presence of specific gene signature rather than the lack of it or decrease in gene dosage levels could present a more reliable parameter for poor-prognosis, we focused on characterizing the gene signature associated with higher dosage genes.

All the 29 higher dosage genes from poor prognosis patients were investigated for cancer association. This search yielded at least 15 genes that were referenced to having functional relationship with some type of cancer. Specifically, increased expressions of Transforming growth factor beta receptor II (TGFBR2), Neuregulin 2 (NRG2) as well as the respective signaling pathways activated by the proteins in ovarian cancer progression and metastasis are well characterized.49-51 TGFBR2 functional effect is impaired by YAP and EZH2 signaling in small cell lung cancer52 and by another protein, GFT2IRD1, in colorectal cancer.53 NRG2 ligand binds with ErbB2 receptors and downstream signaling lead to colorectal cancer and breast cancer progression.54,55 Potential role of Keratin 5 (KRT5) as well as Collagen, type IV, alpha 3 (COL4A3) in invasive metastasis and disease recurrence in ovarian cancer have also been previously known.56,57 Although a defined role for PANXI in ovarian cancer is thus far unknown, it is shown to promote invasive migration in hepatocellular carcinoma.58 Similarly, PKP1 has been shown to be associated with tumor progression and metastasis in prostate cancer and melanoma59,60 while Kinesin superfamily protein 17 (KIF17) is known to be associated with Rho-mediated epithelial cell migration.61 In addition, the poor-prognosis gene signature identified by our study also includes Zinc finger, MIZ-type containing 2 (ZMIZ2) involved in Wnt1/β-catenin signaling in colorectal cancer and papillary thyroid cancer62,63; Netrin B receptor (UNC5B), which is involved on Netrin-1 signaling in gastric cancer cell proliferation via PI3K/AKT pathway64; Disk, Large homolog-associated protein 2 (DLGAP2) is involved in pancreatic cancer through AMPK pathway65; G protein-couple receptor (GPR176) is implicated in breast cancer transcriptional response,66 which is an immune therapy target for ovarian cancer67,68; and Lysine-specific histone demethylase 5C (KDM5C) gene that promotes prostate cancer by repressing PTEN expression.69

Figure 4. Identification of network gene nodes related to cancer among the higher dosage genes of poor compared to favorable prognosis patients. Interaction network nodes of higher dosage genes in circular layout generated using Reactome functional interaction network database on Cytoscape. Higher dosage genes (purple circles with black fonts) and linker genes (green circles with red fonts); solid black lines indicate known interactions and broken black lines are predicted interactions.
Analysis of these 15 genes in TCGA database oncoprint (National Cancer Institute, The Cancer Genome Atlas) using cBioportal, further confirmed that these genes were predominantly amplified, or deleted but not mutated (Supplemental figure 2). These gene amplification/deletions variation among patients suggested that their functional protein expression may vary in the patient tumor samples. Hence, the top 2 proteins identified by Reactome functional database analysis that is, TGFBR2 and ZMIZ2 were tested for their protein expression in the patient tumor samples. About 3% of patients reported in TCGA data show amplification and our sequencing results show higher dosage of TGFBR2 in poor prognosis patients. In contrast, the protein expression, as monitored by TMA, was downregulated in poor prognosis patient tumor samples, thus presenting an apparent inconsistency between the data from the cfDNA analysis and TMA analysis. It should be noted here that TGFBR2 shows increased expression in omental metastases and invasive front of ovarian cancer. Since our TMA does not represent any samples from omental metastases or invasive front of ovarian cancer tissue, it is more likely that our TMA analysis missed the expression profile of TGFBR2. Previous findings that the expression of TGFBR2 is closely associated with ovarian cancer progression also point to a prognostic role for TGFBR2. Further IHC analysis of TMA representing different locales of ovarian cancer tissues should establish the unequivocal role of TGFBR2 as a prognostic biomarker in ovarian cancer liquid biopsy. It should also be noted here that the age difference between the poor-prognosis and favorable-prognosis is significantly different (Table 1). Considering the previous findings that omental metastases show increased expression of TGFBR2, it is possible that the age difference and possibly the associated metastatic stage of the tumor plays a role in presenting TGFBR2 as a cfDNA-based prognostic biomarker in ovarian cancer. Thus, it is possible that age could be a parameter in deciding which biomarker can be used for prognosis. Further analysis with distinct age group, histological sub-types, stage/grade, and spatial localization of the expressed markers is anticipated to consolidate the prognostic biomarker candidacy of cfDNA-gene signatures such as that of TGFBR2.

Interestingly, gene signature for ZMIZ2 shows higher dosage as well as protein upregulation in poor prognosis patient tumor samples. This corroborates with the previous findings that indicated a pro-tumorigenic role for ZMIZ2. Staining of ZMIZ2 on a second cohort of ovarian cancer patients, reiterated the upregulation of ZMIZ2 in poor prognosis patients. Functionally, this is validated by the findings that the expression of ZMIZ2 is correlated with the Wnt/beta-catenin signaling and Wnt-signaling is often dysregulated in
cancers.62,76,77 ZMIZ2 could prove to be a valid prognostic biomarker for ovarian cancer poor prognosis/therapy-resistance. Various oncogenes and tumor suppressors have been identified as prognostic and diagnostic biomarkers for ovarian cancer progression.78 cfDNA based biomarkers are investigated widely for methylation patterns and DNA copy number variations in ovarian cancer patients.79,80 Advances in next generation sequencing allowed our approach to sequence the minimal quantity of cfDNA for gene signature panels.81 Although, the level of amplification of the considered genes may be low, this pilot project indicates presence of specific genes as cfDNA fragments in serum and respective protein expression levels in tumor tissue, which of those can be exploited further as multifactorial definition for prognosis determination in ovarian cancer patients. However, we acknowledge that larger cohort of patients, inclusive of various ethnic background, need to be tested and an unequivocal panel of gene signatures developed to serve as a novel tool for stratification of prognosis among ovarian cancer patients.

Acknowledgements
We thank the Stephenson Cancer Center (SCC) at the University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK and an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103639 for the use of Biospecimen, and Histology, Immunohistochemistry and Microscopy Core, which provided Processing and Embedding/Tissue staining / ImmunoHistochemistry service. We wish to acknowledge the SCC Biospecimen core, for providing the serum and tissue samples and Molecular Biology and Cytometry core for assisting with sequencing the samples supported partially by the National Cancer Institute Grant P30CA225520 of the National Institutes of Health.

Data availability
All the data generated for this publication are included in the paper. The sequencing data generated during the current study are available in the NCBI SRA repository, https://www.ncbi.nlm.nih.gov/sra/PRJNA517159.

ORCID iD
Muralidharan Jayaraman https://orcid.org/0000-0003-3274-877X

Supplemental material
Supplemental material for this article is available online.

REFERENCES
1. Allison KH, Sledge GW. Heterogeneity and cancer. Oncology. 2014;28:772-778.
2. Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer. 2015;137:262-266.
3. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA. Molecular predictors of response of and outcome in ovarian cancer. Crit Rev Oncol Hematol. 2006;60:19-37.
4. Robles AI, Harrison CC. Integration of multiple “OMIC” biomarkers: a precision medicine strategy for lung cancer. Lung Cancer. 2017;107:50-58.
5. T. Baiardi K, Amarsi M, Kandhor AH, Afije S. Prediction of therapy response in ovarian cancer: where are we now? Crit Rev Clin Lab Sci. 2017;54:233-266.
6. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l’homme. C R Sciences Soc Biol Fil. 1948;142:241-243.
7. Laron SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer. 1977;37:64-650.
8. Chang Y, Tolban B, Nie X, Zhi X, Hu M, He B. Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring. Ther Clin Risk Manag. 2017;13:1363-1374.
9. Siegel RL, Miller KD, Fuchs HE. Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
10. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999;4:87-94.
11. Gore ME, Fryatt I, Wilshe W, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207-211.
12. Markman M, Rottenberg S, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1999;17:389-393.
13. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502-516.
14. Borst P, Rottnering S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle. 2008;7:1353-1359.
15. Stoddard B, Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets. 2009;9:354-365.
16. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9-23.
17. Gordon AN, Pleagge JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
18. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2881-2889.
19. Kamar AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann NY Acad Sci. 2006;1075:230-234.
20. Liggert TE, Melnikov A, Yi Q, et al. Distinctive DNA methylation patterns of cell free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011;120:113-120.
21. Zachariah RR, Schmidt S, Buerki N, Radpour R, Holzgrewe W, Zhong X. Levels of circulating-cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol. 2008;112:843-850.
22. No JHI, Kim K, Park KH, Kim YB. Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res. 2012;32:3467-3471.
23. Cheng X, Zhang L, Chen Y, Qing C. Circulating cell-free DNA and circulating tumor cells, the ‘liquid biopsies’ in ovarian cancer. J Ovarian Res. 2017;10:75.
24. Steffenes KD, Madson CV, Andersen RP, Waldstrom M, Adami P, Jakobsen A. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. Eu J Cancer. 2014;50:2661-2668.
25. Dobrzycka B, Terlikowski SJ, Kinalski M, Kowalczyk O, Niklinska W, Chyczewski L. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Ann Oncol. 2011;22:1313-1319.
26. Kamar AA, Baldwin M, Uebelauer D, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;114:1918-1925.
27. Chakraborty PK, Mustafi SB, Xiong X, et al. MUC1 drives glycosylation and cho- lightmoresistancerelatedcancer. Nat Commun. 2017;8:14634.
28. Thomas PD, Campbell MJ, Rejaizwa A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003;13:2129-2141.
29. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol Med. 2005;103:89-101.
30. Jayaraman M, Radhakrishnan R, Mathews CA, et al. Identification of novel diagnostic and prognostic markers: signatures in endometrial cancer. Genes Cancer. 2017;8:566-576.
31. Schwaederle M, Chattopadhyay M, Kato S, et al. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res. 2017;77:5419-5427.
32. Stout M, Arke P, Maurice P, Luyten J, Leducry C, Belianjski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46:318-322.
33. Li W. Volcano plots in analyzing differential expressions with mRNA microarrays. J Bioinform Comput Biol. 2012;10:1231003.
34. Dalman MR, Deeter A, Nimishakari G, Duan ZH. Fold change and p-value cutoffs significantly alter microarray interpretations. *BMC Bioinformatics*. 2012;13(Suppl 2):S11.

35. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionization radiation response. *Proc Natl Acad Sci*. 2001;98:5116-5121.

36. Wu G, Hwang P. Computational interaction network construction and analysis for Disease Discovery. *Methods Mol Biol*. 2017;1558:235-253.

37. Högborg T, Gilmelius B, Nygren P; SBU-Group. Swedish Council of Technol- ogy Assessment in Health Care. A systematic overview of chemotherapies effects in ovarian cancer. *Acta Oncol*. 2001;40:340-360.

38. Calado E, Brogioni M, Marabesi M. Genetic markers for prediction of treatment outcomes in ovarian cancer. *Pharmacogenomics*. 2014;14:401-410.

39. Choi JJ, Reich CF 3rd, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. *Immunology*. 2005;115:56-64.

40. Cheng L, Wu S, Zhang K, Qing Y, Xu T. A comprehensive overview of exo- somes in ovarian cancer: emerging biomarkers and therapeutic strategies. *J Ovar- ian Res*. 2017;10:73.

41. Nagata S, Nagase H, Kawane K, Mukea N, Fukuyama H. Degradation of chro- mosomal DNA during apoptosis. *Cell Death Differ*. 2003;10:108-116.

42. Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. *Comput Struct Biotechnol J*. 2018;16:370-378.

43. Grabusch S, Brouskhos AJ, Holdenrieder S, et al. Putative origins of cell-free DNA in humans: A review of active and passive nuclear acid release mecha- nisms. *Int J Mol Sci*. 2020;21:8062-8086. doi: 10.3390/ijms21280862

44. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantifications and evidence for their origin from apoptotic and necrotic cells. *Cancer Res*. 2010;70:1659-1665.

45. Kashiwagi H, R. Functional interaction network of genuine amplification and deletion in cancer. *Hum Mol Cell*. 2000;9:135-141.

46. Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and cir- culating tumor DNA. *Annu Rev Med*. 2012;63:199-215.

47. Gileva K, Yeiko N, Kostyuk S, Izhevskaya V, Baranov A. Oxidized extracel- lular-DNA as a stress signal that may modify response to anticancer therapy. *Cancer Lett*. 2015;356:22-33.

48. Thiery AR, El Messaoudi S, Ghan PB, Anker P, Stroun M. Origins, struc- tures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev*. 2016;35:347-356.

49. He C, Li X, Hua G, et al. YAP forms autocline loops with the ERBB pathway to regulate ovarian cancer initiation and progression. *Oncogene*. 2015;34: 6040-6054.

50. Papanastasiou AD, Pampalakis G, Katsaros D, Sotiropoulou G. Netrin-1 over- expression is a predictive of ovarian malignancies. *Oncotarget*. 2011;2:363-367.

51. Nagaoka T, Kitaura K, Miyata Y, et al. Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with ovarian cancer. *Acta Oncol*. 2015;40:374-376.

52. Davila C, Reith I, Wang Y, et al. The functional consequence and prognostic value of dosage sensitivity in ovarian cancer. *Mol Biogegn. 2017;13:380-391.

53. Liu M, Fan H, Zhang F, et al. Screening of differentially expressed genes among various TMM stages of high adenocarcinoma by genomewide gene expression analysis. *African J Cancer Prev*. 2014;14:6281-6289.

54. Lee SH, Zhu C, Peng Y, Johnson DT, Lehrmann L, Sun Z. Identification of a novel role of ZMIZ2 protein in regulating the activity of the Wnt/β-catenin sig- naling pathway. *J Biol Chem*. 2013;288:35913-35924.

55. Kone M, Pullen TJ, Sun G, et al. LKB1 and AMPK differentially regulate pan- creatic β-cell identity. *Endo J*. 2018;24:4972-4985.

56. Wang T, Nakagawa S, Miyake T, et al. Identification and functional characteri- sation of N-linked glycosylation of the orphan G protein-coupled receptor gp130. *Sci Rep*. 2020;10:4429.

57. Takada Y, D'OPR14 induces IL17a gene expression through the RORγ/BAZ1B/ RSKS2 complex. *Mol Cell Biol*. 2015;35:344-355.

58. Wang T, Wang X, Fan X, et al. Coexpression network analysis identified that plakophilin 1 is associated with the metastasis in human melanoma. *Biomed Pharmacother*. 2019;111:1234-1242.

59. Shimada S, Masuda T, Kobayashi Y, et al. GTF2IRD1 on chromosome 7 is a therapeutic target in ovarian cancer. *Virology*. 2013;461:379-390.

60. Wang HZ, Wang F, Chen PW, et al. Coexpression network analysis identified that plakophilin 1 is associated with the metastasis in human melanoma. *Biomed Pharmacother*. 2019;111:1234-1242.

61. Acharya BR, Espenel C, Libanje F, et al. KIF17 regulates RhoA-dependent actin remodeling at epithelial cell-cell adhesions. *J Cell Sci*. 2016;129:957-970.

62. Zhu Y, Gu L, Xin X, et al. LIN7C00265 promotes colorectal tumorigenesis via ZMIZ2 and USP7-mediated stabilization of β-catenin. *Cell Death Differ*. 2020;27:1316-1327.

63. Yu D, Liu Y, Wang L, et al. Tumor necrosis factor is characterized by altered expression of genes involved in the sumoylation process. *J Biol Regul Homeost Agents*. 2015;29:655-662.

64. Yin K, Wang L, Zhang X, et al. Netrin-1 promotes gastric cancer cell prolifera- tion and invasion via the receptor neogenin through PI3K/AKT signaling path- way. *Oncotarget*. 2017;8:51177-51189.

65. Kone M, Pullen TJ, Sun G, et al. LKB1 and AMPK differentially regulate pan- creatic β-cell identity. *Endo J*. 2018;24:4972-4985.

66. Wang T, Nakagawa S, Miyake T, et al. Identification and functional characteri- sation of N-linked glycosylation of the orphan G protein-coupled receptor gp130. *Sci Rep*. 2020;10:4429.

67. Yamamura S, Matsumura N, Mandai M, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential ther- apeutic target in ovarian cancer. *Int J Cancer*. 2012;130:20-28.

68. Lo Sardo F, Pulito C, Sacconi A, et al. YAP/TAZ and E2H2 synergize to impair tumor suppressor activity of TGFB2 in non-small cell lung cancer. *Cancer Lett*. 2021;500:51-63.

69. Nambara S, Masuda T, Kubayashi Y, et al. GTPF2 HDR1 on chromosome 7 is a novel oncogene regulating the tumor-suppressor gene TGFB2 in colorectal cancer. *Cancer Sci*. 2020;111:343-355.

70. Nagaoa T, Kitaura K, Miyata Y, et al. Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer. *Med Mol Exp*. 2016;13:3514-3520.

71. Linder C, Révilllon F, Lhotellier V, Hornez L, Peyrat JP, Bonnettre J. Relationship- ships between progestosterone receptor isoforms and the HER2/Erbb receptors and ligands network in 299 primary breast cancers. *Int J Biol Markers*. 2012;27:e111-e117.

72. Siakamkour-Reihani S, Owzar K, Jiang C, et al. Prognostic significance of dif- ferential expression of angiogenic genes in women with high-grade serous ovar- ian carcinoma. *Gynecol Oncol*. 2015;139:23-29.

73. Ricciardielli C, Lokman NA, Pyragius CE, et al. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. *Oncotarget*. 2017;8:17819-17832.